NCT04717908 - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

June 22, 2024

Study Completion Date

June 22, 2024

Conditions

Multidrug Resistant Tuberculosis

Interventions

DRUG

Bedaquiline

400 mg once daily for 2 weeks then 200mg 3 times per week;

DRUG

Pyrazinamide

1500 mg daily

DRUG

Linezolid

600 mg daily

DRUG

Cycloserine

≤50kg 500 mg daily, \>50kg 750mg daily;

DRUG

Clofazimine

100 mg daily;

Trial Locations (15)

200040

Huashan Hospital of Fudan University, Shanghai

Unknown

The Third People's Hospital of Shenzhen City, Shenzhen

Guiyang Public Health Treatment Center, Guizhou

The Sixth People's Hospital of Zhengzhou, Zhengzhou

Hunan Chest Hospital, Changsha

Huaihua first people's Hospital, Huaihua

Shanxi Provincial Tuberculosis Control Institute, Xi’an

Chest Hospitalof Xinjiang Uygur Autonomous Region of PRC, Ürümqi

Baoshan People's Hospital, Baoshan

Yunnan Provincial Infectious Disease Hospital, Kunming

Hangzhou Red Cross Hospital, Hangzhou

Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital), Ningbo

Taizhou Enze medical center Enze Hospital, Taizhou

The Central Hospital of Wenzhou City, Wenzhou

Jiangxi Chest Hospital, Nanchang

All Listed Sponsors

lead

Huashan Hospital

OTHER